A New Treatment of Meniere's Disease

Dowdy, Elizabeth G.; Goksen, Nesrin; Arnold, Godfrey E.; Moore, William T.; Fabian, Leonard W.

doi:10.1001/archotol.1965.00760010496007

Cited by 20 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, there are reports of the occurrence of a Ménière's like-syndrome after the use of epidural morphine [86]. The combination of phentanyl (a synthetic primary MOR agonist 100 times more potent than morphine) and droperidol (an antidopaminergic drug used as an antiemetic and antipsychotic) has been used for the treatment of Ménière's disease crises; this mixture has a rapid action and results in a complete suppression of vestibular activity in normal subjects and in those with Ménière's disease [32]. Administration of a single dose of phentanyl and droperidol combination (droperidol 5 mg, phentanyl 0.1 mg) to patients undergoing acute episodes of vestibular disease (vestibular neuronitis and Ménière's disease) was effective in the following symptoms and/or signs: nausea, vertigo, nystagmus, the positive past-pointing test and the Romberg test [71].…”

Section: Drugs With Effects On Neurotransmitters and Neuromodulator Rmentioning

confidence: 99%

Neuropharmacology of Vestibular System Disorders

Soto¹,

Vega²

2010

View full text Add to dashboard Cite

This work reviews the neuropharmacology of the vestibular system, with an emphasis on the mechanism of action of drugs used in the treatment of vestibular disorders. Otolaryngologists are confronted with a rapidly changing field in which advances in the knowledge of ionic channel function and synaptic transmission mechanisms have led to the development of new scientific models for the understanding of vestibular dysfunction and its management. In particular, there have been recent advances in our knowledge of the fundamental mechanisms of vestibular system function and drug mechanisms of action. In this work, drugs acting on vestibular system have been grouped into two main categories according to their primary mechanisms of action: those with effects on neurotransmitters and neuromodulator receptors and those that act on voltage-gated ion channels. Particular attention is given in this review to drugs that may provide additional insight into the pathophysiology of vestibular diseases. A critical review of the pharmacology and highlights of the major advances are discussed in each case.

show abstract

Section: Drugs With Effects On Neurotransmitters and Neuromodulator Rmentioning

confidence: 99%

Neuropharmacology of Vestibular System Disorders

Soto¹,

Vega²

2010

View full text Add to dashboard Cite

show abstract

“…Because of the known direct suppressive effect on caloric nystagmus (15), this hypothesis deserves consideration and further investigation. Inasmuch as the pathophysiology of Meniere's disease has been the subject of considerable debate for decades and still remains unknown, this theory must also remain at the level of conjecture.…”

Section: Discussionmentioning

confidence: 99%

“…In the 1960s Innovar was found to have a specific suppressive effect on the vestibular sensitivity and symptoms. Dowdy et al (15) performed caloric tests before and one week after a dose of Innovar and found complete suppression of caloric nystagmus in 8 of 9 subjects and a marked reduction in the ninth. Subjects receiving fentanyl alone or droperidol alone had no or only a slight reduction in caloric responses.…”

Section: Introductionmentioning

confidence: 99%

Innovar Treatment for Meniere's Disease

Gates

1999

Acta Oto-Laryngologica

View full text Add to dashboard Cite

Patients with intractable vertigo due to clinical Meniere's disease were offered treatment with Innovar, a neurolept analgesic. The patients were from a single clinical practice, had failed conventional dietary and medical treatment and were eligible on clinical grounds for endolymphatic sac surgery. After a follow-up of 2-8 years, 58% of patients had long-lasting relief of vertigo. Hearing was not affected. Risk factors for a favorable response were male gender, fluctuating hearing, and early stage of the disorder. Innovar is a safe, cost-effective second-line therapy for patients with Meniere's disease who have failed conventional first-line medical therapy.

show abstract

“…A report of the drug Innovar (droperidol and fentanyl citrate) being used with good results in patients with Meniere's disease recently appeared in the literature. 1 Because of the unpredictable remissions and exacerbations, it is difficult to evaluate whether or not a drug has genuinely altered the natural course of Meniere's disease. The following study was performed in order to determine the effect of Innovar on nystagmus induced by ethanol in normal human volunteers.…”

mentioning

confidence: 99%